Skip to main content

Table 3 Assessing the predictive effect of each malaria antibody and FCGR3B polymorphisms on the risk of malaria

From: Evaluating the predictive performance of malaria antibodies and FCGR3B gene polymorphisms on Plasmodium falciparum infection outcome: a prospective cohort study

Model specification

LR, p-value

BCV AUROC

BCV BS (%)

RMSE

R2

F + log.IgGAMA1

12.23, 0.0301

55

10

0.3511

2.0

F + log.IgG1AMA1

14.09, 0.0223

57

10

0.3501

2.0

F + log.IgG2AMA1

5.76, 0.8058

49

12

0.3400

1.0

F + log.IgG3AMA1

10.41, 0.7668

54

12

0.3525

2.0

F + log.IgG4AMA1

7.03, 0.7668

50

12

0.3439

3.0

F + log.IgGGLURPR0

7.41, 0.6501

51

12

0.3514

1.0

F + log.IgG1GLURPR0

6.93, 0.6987

51

12

0.3518

0.0

F + log.IgG2GLURPR0

6.38, 0.7528

50

12

0.3512

1.0

F + log.IgG3GLURPR0

5.99, 0.7872

49

12

0.3532

1.0

F + log.IgG4GLURPR0

6.13, 0.7716

50

12

0.3517

1.0

F + log.IgGGLURPR2

7.98, 0.5923

53

12

0.3518

1.0

F + log.IgG1GLURPR2

8.62, 0.6135

52

12

0.3512

1.0

F + log.IgG2GLURPR2

6.81, 0.7672

49

12

0.3514

1.0

F + log.IgG3GLURPR2

6.68, 0.7754

50

12

0.3812

1.0

F + log.IgG4GLURPR2

6.18, 0.7671

50

12

0.3909

2.0

F + log.IgGMSP1

6.60, 0.7302

51

12

0.3609

0.0

F + log.IgG1MSP1

6.03, 0.7812

50

12

0.3512

1.0

F + log.IgG2MSP1

6.53, 0.7369

50

12

0.3517

0.0

F + log.IgG3MSP1

5.78, 0.8059

49

12

0.3518

0.0

F + log.IgG4MSP1

5.81, 0.8032

49

12

0.3547

1.0

F + log.IgGMSP3

8.08, 0.5816

52

12

0.3558

0.0

F + log.IgG1MSP3

8.41, 0.6146

52

12

0.3678

1.0

F + log.IgG2MSP3

5.96, 0.7897

50

12

0.3579

2.0

F + log.IgG3MSP3

6.68, 0.7217

50

12

0.3510

1.0

F + log.IgG4MSP3

5.81, 0.8029

50

12

0.3512

2.0

F + Additive c.108C>G

7.81, 0.6743

51

12

0.3484

0.5

F + Additive c.114T>C

6.3, 0.8108

49

12

0.3501

0.5

F + Additive c.194A>G

7.42, 0.7103

50

12

0.3474

1.1

F + Additive c.233C>A

8.76, 0.5557

51

12

0.3470

1.3

F + Additive c.244A>G

8.51, 0.6066

51

12

0.3464

1.6

F + Additive c.316A>G

6.51, 0.7894

50

12

0.3483

0.6

F + Dominant c.108C>G

7.83, 0.6025

52

12

0.3455

2.1

F + Dominant c.114T>C

5.76, 0.8029

50

12

0.3458

2.0

F + Dominant c.194A>G

7.44, 0.6411

51

12

0.3467

1.5

F + Dominant c.233C>A

8.99, 0.0456

58

11

0.3166

2.4

F + Dominant c.244A>G

5.79, 0.8011

49

12

0.3491

0.1

F + Dominant c.316A>G

6.46, 0.7319

51

12

0.3476

1.0

F + Recessive c.108C>G

6.05, 0.7769

49

12

0.3454

2.2

F + Recessive c.114T>C

6.23, 0.7597

49

12

0.3487

0.3

F + Recessive c.194A>G

6.07, 0.7731

49

12

0.3480

0.7

F + Recessive c.233C>A

6.36, 0.7468

50

12

0.3500

0.4

F + Recessive c.244A>G

8.26, 0.5566

52

12

0.3470

1.3

F + Recessive c.316A>G

6.1, 0.7735

49

12

0.3479

0.8

  1. F: Penalized maximum likelihood model (PMLE.model), LR: Likelihood Ratio test statistic; BCV: Bootstrap cross-validation; RMSE: Root Mean Squared Error; R2: Proportion of explained variation in predicted risk; AUCROC: Area Under the Receiver Operating Characteristic curve, BS: Brier score
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us